Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Marqeta Inc (MQ) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

Marqeta IncTrade
Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Marqeta Inc vs Recursion Pharmaceuticals Inc — how do they compare? Marqeta Inc trades at $15.52 (market cap $1.62B), while Recursion Pharmaceuticals Inc trades at $3.36 (market cap $1.78B). The key difference: Marqeta Inc and Recursion Pharmaceuticals Inc are close in size by market cap. Which is the better fit depends on your goals.

MQRXRX
Market Cap
$1.62B$1.78B
Sector
TechnologyHealth
52-Week High
$26.00$6.79
52-Week Low
$15.04$2.84
Enterprise Value
$939.53M$1.30B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Marqeta Inc

No Aura AI signal available yet.

Recursion Pharmaceuticals Inc

RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.

Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Marqeta Inc

Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.

Read more on MQ

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX